Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1621 1622 1624 1625 1629 1699
This examiner grants 81% of resolved cases
Noble E Jarrell is an examiner in Tech Center 1600 and Art Unit 1612, with a volume of 1049 resolved cases. The allowance rate is 81.1 percent, and the median days to allowance is 1084. These metrics indicate the likelihood of success and the prosecution timeline for the 1049 resolved cases that have reached a final disposition. This large volume of cases provides a stable dataset for these performance indicators.
The interview lift is 9.7 percent, which shows a positive impact from direct engagement compared to the 81.1 percent base allowance rate. While the 81.1 percent rate is already strong, the 9.7 percent lift suggests that interviews can help resolve specific hurdles. Practitioners should factor in the 1084 days to allowance when developing their strategy, noting that the 9.7 percent lift is a tool for reaching the 81.1 percent allowance outcome. The 1049 resolved cases underscore the consistency of these results.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18091139 | CURABLE RESIN COMPOSITION, CURED PRODUCT, DIFFRACTIVE OPTICAL ELEMENT, AND MULTILAYER DIFFRACTIVE OPTICAL ELEMENT | Final Rejection | FUJIFILM Corporation |
| 18009126 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS V | Non-Final OA | BASF SE |
| 18286740 | E3 LIGASE BINDERS AND USES THEREOF | Final Rejection | President and Fellows of Harvard College |
| 17629303 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | University of Virginia Patent Foundation |
| 18692541 | DIROXIMEL FUMARATE PARTICLES HAVING IMPROVED FLOW PROPERTIES AND METHODS OF MAKING SAME | Non-Final OA | BIOGEN MA INC. |
| 18554231 | ANTICANCER THERAPY | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17917910 | METHODS OF SYNTHESIZING CAROTENOIDS | Non-Final OA | L.E.A.F. HOLDINGS GROUP LLC |
| 18528215 | RAPAMYCIN ANALOGS AND USES THEREOF | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18292918 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | Non-Final OA | Hadasit Medical Research Services and Development Ltd. |
| 18290252 | USE OF RAGE INHIBITORS TO TREAT CANCER-RELATED COGNITIVE DECLINE | Non-Final OA | Georgetown University |
| 18235285 | PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTIONS | Non-Final OA | The U.S.A., as Represented by the Secretary, Department of Health and Human Services |
| 18695384 | POLYCYCLIC FUSED RING DERIVATIVES AND USE THEREOF | Non-Final OA | Jacobio Pharmaceuticals Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy